Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 9/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018295 | 0.82 | PLA2G1B (0.48) | PLA2G1BBAZ2BBAZ2APLA2G2A | |
| SCHEMBL7015571 | 0.74 | GAA (0.42) | BAZ2BBAZ2AHCRTR1HCRTR2 | |
| SCHEMBL7013421 | 0.74 | PLA2G1B (0.59) | PLA2G1BBAZ2BBAZ2APLA2G2A | |
| SCHEMBL7010592 | 0.70 | PLA2G1B (0.61) | PLA2G1BPLA2G2A | |
| SCHEMBL8324082 | 0.69 | PLA2G1B (0.47) | PLA2G1BPLA2G2A | |
| SCHEMBL7009863 | 0.66 | PLA2G1B (0.66) | PLA2G1BPLA2G2A | |
| SCHEMBL7012842 | 0.66 | PLA2G1B (0.81) | PLA2G1BPLA2G2A | |
| SCHEMBL7011897 | 0.66 | TAS1R3 (0.45) | PLA2G1BBAZ2BBAZ2APLA2G2A | |
| SCHEMBL7011415 | 0.65 | LTA4H (0.41) | PLA2G1BBAZ2BBAZ2A | |
| SCHEMBL8766668 | 0.63 | LTA4H (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |